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ROLE OF INTERLEUKIN-1, TUMOR NECROSIS FACTOR a, AND
INTERLEUKIN-6 IN CARTILAGE PROTEOGLYCAN
METABOLISM AND DESTRUCTION
Effect of In Situ Blocking in Murine Antigen- and Zymosan-Induced Arthritis
FONS A. J. v a n  d e  LOO, LEO A. B. JOOSTEN, PETER L. E. M
ONNO J. ARNTZ WIM
Objective. To determine the involvement of inter­
leukin-1 (IL-1), tumor necrosis factor (TNF), and IL-6 
in the cartilage pathology of murine antigen-induced 
arthritis (AIA) and zymosan-induced arthritis (ZIA).
Methods. Arthritis was induced by intraarticular 
injection of zymosan in naive mice or by subcutaneous 
injection of methylated bovine serum albumin in sensi- 
tized animals. Mini-osmotic pumps releasing human 
recombinant IL-1 receptor antagonist (IL-lra) protein 
were implanted intraperitoneally 2 days before arthritis 
induction, and neutralizing antibodies directed against 
murine IL-1 a, IL-lß ,  TNF a, or IL-6 were administered 
1 day before. Proteoglycan (PG) synthesis and degrada­
tion were assessed in patellar cartilage.
Results. Murine IL-1 a: and IL-1/3 injected in-
■
traarticularly at doses of 0.1-100 ng suppressed chon­
drocyte PG synthesis. The highest dose of TNF tested 
(100 ng) decreased PG synthesis marginally. In contrast, 
the maximum dose of IL-6 (1 fig) stimulated PG syn­
thesis 2 days after injection. Treatment of AIA with 
neutralizing monoclonal antibodies against either TNF« 
or IL-6 did not reduce either the PG degradation or the 
suppression of its synthesis. However, treatment with 
anti-IL-1 (a  + ß) polyclonal antibodies totally pre­
vented PG suppression, although the initial breakdown 
of PG was unaffected. This effect was confirmed when
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IL-lra was administered in high doses. Moreover, treat­
ment of ZIA with anti-IL-1 (a  + ß), but not with
*
anti-TNF, resulted in normal PG synthesis, confirming 
the key role played by IL-1 in the inhibition of PG 
synthesis. Treatment of AIA with anti-IL-1 did not 
affect inflammation during the acute phase, but a sig­
nificant reduction of ongoing inflammation was noted at
»
day 7, and there was a marked reduction in the loss of 
cartilage PG.
Conclusion. The suppression of PG synthesis in 
both ZIA and AIA in mice is due to the combined local 
action of IL-1 (a  +  ß), and neither IL-6 nor TNF is 
involved. Moreover, the normalization of PG synthesis 
brought about by blocking of IL-1 ameliorates the 
cartilage damage associated with AIA.
Rheumatoid arthritis (RA) is a systemic illness 
characterized by chronic inflammation of the joints 
and severe cartilage abnormalities, such as joint space 
narrowing. Tumor necrosis factor (TNF), interleukin-1 
(IL-1), and IL-6 are clearly involved in the arthritic 
process since all 3 cytokines are present in synovial 
fluid and can be detected immunohistochemically in 
the inflamed rheumatoid synovium (1,2). Furthermore, 
both local and systemic levels of each cytokine corre­
spond to disease activity (3-5), and TNF and IL-1 
have profound catabolic effects on articular cartilage 
explants from numerous species (6,7).
The spontaneous production of IL-1 by rheu­
matoid synoviocytes can be inhibited by anti-TNF 
antibodies (8), suggesting that the activity of TNF 
occurs earlier in the cascade than that of IL-1, whereas 
IL-6 occupies a position later in the cascade, being 
produced in response to either TNF or IL-1 (9,10).
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Furthermore, IL-1 induces IL-6 synthesis by chondro­
cytes and is a cofactor in the IL -l-induced  suppres­
sion o f proteoglycan (PG) synthesis (11).
Intraarticular injections o f T N F and IL-1 cause 
an influx of neutrophils into the joint and synovitis 
similar to that seen in experimental arthritis, but only 
IL-1 results in marked depletion o f the cartilage matrix 
(12-15). In vitro, TNF is also less potent than IL-1 in 
suppressing PG synthesis in cartilage explants (16,17).
Direct evidence that TNF and IL-1 play a role 
in the pathogenesis of experimental arthritis has been 
obtained in animal models in which blocking o f the 
action o f these cytokines has been shown to delay the 
onset of collagen-induced arthritis (CIA), suppress 
inflammation, and ameliorate cartilage destruction that 
corresponds to the antiinflammatory response (18-23). 
Those studies focused on macroscopic scoring o f the 
affected joints and histologic evaluation, but did not 
analyze cartilage metabolism in detail, nor did they 
investigate the effect o f anti-IL-6 treatment.
We therefore undertook the present investiga­
tion o f the potency o f IL-1, IL-6, and TN F in PG 
synthesis and degradation of murine cartilage, and the 
effect o f blocking of endogenous IL-1, TN F, or IL-6 in 
murine arthritis induced either by antigen or by zym o­
san (24,25), a potent inducer o f both IL-1 and TN F in 
vivo (26,27). The effect o f treatment with neutralizing 
antibodies on acute joint swelling and inflammation 
was assessed, and PG synthesis and degradation were 
measured in cartilage.
MATERIALS AND METHODS
Animals. Male C57B1/6 mice were obtained from our 
institution’s breeding facilities and were fed a standard diet 
and tap water ad libitum.
Cytokines. Purified and biologically active mature 
murine recombinant IL-1 a and IL-1/3 were generously do­
nated by I. G. Otterness (Pfizer Central Research, Groton, 
CT), purified murine recombinant IL-6 by G. Ciliberto 
(IRBM, Rome, Italy), and purified recombinant human IL-1 
receptor antagonist (IL-lra) by Synergen (Boulder, CO). 
Murine recombinant TNFa (carrier free) was purchased 
from R & D Systems (Minneapolis, MN).
Neutralizing anticytokine antibodies. Rat anti-mouse 
TNFa monoclonal antibody (Vlq) was kindly donated by P. 
H. Krammer (German Cancer Research Center, Heidel­
berg), rabbit anti-mouse TNF polyclonal antiserum by S. L. 
Kunkel (University of Michigan Medical School, Ann Ar­
bor), and another rabbit anti-mouse TNF polyclonal anti­
serum by G. E. Grau (University of Geneva, Geneva, 
Switzerland). Rabbit anti-mouse IL-6 polyclonal antiserum 
was donated by M. Fuller (University of Alabama at Bir­
mingham). Rat anti-mouse IL-6 monoclonal antibody was
purchased from Genzyme (Cambridge, MA). Neutralizing 
capacity was verified with specific bioassays for the cytokines.
Generation of rabbit anti-mouse IL-1 antiserum. Poly­
clonal antibodies directed against each type of murine re­
combinant IL-1 were prepared by immunization according to 
the method of Hogquist et al (28), with some modifications. 
Briefly, 250 ¡xg IL-1 in 2.25 ml phosphate buffered saline 
(PBS) was suspended in 500 fxi aluminum hydroxide (Imject 
Alum; Pierce, Rockford, IL), which was injected into female 
New Zealand white rabbits in 4 subcutaneous injections of 
500 /d each. A further 4 subcutaneous injections of 500 /xl 
Freund’s complete adjuvant (FCA)/PBS were given in sites 
adjacent to the IL-l/alum injection sites. Every 4-6 weeks, 
rabbits received 50 /xg IL-1 suspended in alum in 3 divided 
doses, Freund’s incomplete adjuvant/PBS subcutaneously in 
adjacent sites, and 5 fxg IL-1 intravenously. Ten days after 
every booster, 50 ml of blood was aspirated and coagulated, 
and serum was stored at -70°C, and decomplemented at 
56°C before use.
Purification and characterization of rabbit anti-IL-1 
antibodies. Immunoglobulins were purified by affinity 
chromatography separation on a protein G-Sepharose 
CL-4B column. Immunoglobulins (IgG) were eluted from the 
column with 0.1 M  glycine HC1, pH 3.0, and immediately 
neutralized with 50 mM Tris HCl, pH 8.0. IgG fractions were 
then pooled, concentrated, and dialyzed against PBS at 
ambient temperature. Antibodies directed against the a or ß 
form of IL-1 were tested in vitro for their neutralizing 
capacity, and it was found that dilutions in the range of 
1:64,000 to 1:128,000 could fully block 5 pg/ml IL-1 (lowest 
plateau concentration) in the NOB1 proliferation assay. 
Antibodies showed no neutralizing cross-reactivity against 
each other or against IL-2 (which was tested in the CTLL 
proliferation assay), IL-4 (in the CT.4.S proliferation assay), 
IL-6 (in the B9 proliferation assay), or TNFa (in the L929 
cytotoxicity assay). The anti-IL-1 antibodies had a half-life 
of >3 days in the circulation.
Induction of antigen-induced arthritis. Mice ages 8-10 
weeks were immunized by 2 subcutaneous injections into the 
flank skin and 2 into the footpad of both forelegs, with a total 
of 100 /Ag methylated bovine serum albumin (mBSA; Sigma, 
St. Louis, MO) suspended in 100 /xl FCA per animal. 
Heat-killed Bordetella pertussis at 2 x 109 organisms (Na­
tional Institute of Public Health, Bilthoven, The Nether­
lands) was administered intraperitoneally as an additional 
adjuvant. Two subcutaneous booster injections with 100 fxg 
mBSA/FCA were given in the neck region on day 7. Arthritis 
was induced 14 days after these injections, by intraarticular 
injection of 60 ug mBSA in 6 ix\ saline into the right knee
jo in t.
Induction of zymosan-induced arthritis. A homoge­
neous suspension of 30 mg zymosan A (Saccharomyces 
cerevisiae), dissolved in 1 ml endotoxin-free saline, was 
obtained by boiling twice followed by sonic émulsification. 
Arthritis was induced by intraarticular injection of 180 /xg 
zymosan into the right knee.
Assessment of joint swelling. Animals were injected 
subcutaneously with 10 /xd 99mtechnetium pertechnetate
C
the isotope accumulates in the knee due to the increased 
blood flow and edema. The amount of " mTc was determined
99mTc) in 0.2 ml saline in the neck region. After 15 minutes,
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Table 1. In vivo effects of interleukin-1 (IL-1), tumor necrosis factor (TNF), and IL-6 on proteoglycan (PG) synthesis*
Dose, ng/joint
PG synthesis (% of normal cartilage)
IL-1 a, day 1 IL-1/3, day 1 TNFa, day 1 TNFa, day 2 IL-6, day 1 IL-6, day 2
0.1 70 ± 12 (6)t 90 ± 17 (6) ND ND ND ND
0.3 65 ±  17 (6)t 72 ± 14 (6)t ND ND ND ND
1 50 ± 7 (6)t 54 ± 13 (6)t 97 ± 37 (11) 148 ± 23 (6) 81 ± 10 (6) 94 ± 21 (6)
10 43 ± 9 (6)$ 48 ± 15 (6)* 91 ± 29 (24) 113 ± 19 (19) 105 ± 26 (6) 105 ± 33 (12)
100 47 ± 9 (6) 44 ± 7 (6)t 80 ± 17 (12)+ 79 ± 29 (25) 103 ± 23 (6) 120 ± 22 (12)
1,000 ND ND ND ND 104 ± 24 (12) 132 ± 23 (18)+
* Murine recombinant IL-1, TNF, or IL-6 was injected into the right knee joint cavity of mice. PG synthesis was determined by 35S 0 4 
incorporation ex vivo and is expressed as a percentage of the normal synthesis in patellae of joints injected with saline. Values are the mean 
±  SD; values in parentheses are the number of animals per group. ND = not determined, 
t  P  <  0.05 versus saline-injected joints, by Mann-Whitney U test of cpm values. 
t  P <  0.01 versus saline-injected joints, by Mann-Whitney U test of cpm values.
by external gamma counting. Joint swelling was expressed 
as the ratio of the " mTc uptake in the inflamed knee joint to 
that in its noninflamed counterpart, with ratios >1.1 indicat­
ing joint swelling.
Assessment of proteoglycan synthesis. Six patellae 
were prepared so as to minimize the amount of adjoining 
synovium, tendon, and muscle, and placed in 2 ml RPMI- 
HEPES medium (Flow Laboratories, Irvine, Scotland) sup­
plemented with gentamicin (50 mg/liter), L-glutamine (2 
mM), and 40 /xCi 35S-sulfate. At the end of a 3-hour 
incubation, patellae were fixed in 10% formalin, decalcified 
in formic acid (4%), dissected, and then dissolved in 0.5 ml 
Lumasolve (Hicol, Oud-Beijerland, The Netherlands). The 
35S content of each patella was measured by liquid scintilla­
tion counting and expressed as counts per minute.
Assessment of proteoglycan breakdown. Mice were 
injected with 50-100 /¿Ci 3^ S-sulfate into the peritoneal 
cavity 2 days before induction of arthritis, and a further 2 
days later, patellae were dissected and processed to measure 
the 35S 04 content as described above.
Glycosaminoglycan measurements in patellar carti­
lage. Patellae were fixed in ethyl alcohol (96%) and decalci­
fied in formic acid, after which the cartilage layer could be 
stripped from its underlying bone and subsequently digested 
overnight at 60°C in 200 ¡xl of 5 mg/ml papain (type IV; 
Sigma) in 0 AM  sodium acetate, pH 6.5, 10 mM L-cysteine, 
and 50 mM disodium EDTA per patella. The PG content per 
patella was estimated by dimethylmethylene blue dye bind­
ing at 535 nm, using the colorimetric method of Farndale et 
at (29).
Histologic processing and analysis of knee joints. Knee 
joints were dissected, fixed, decalcified, dehydrated, and 
embedded in paraffin. Standard frontal sections of 7 ¡xm were 
prepared, stained with Safranin O, and counterstained with 
fast green. Cartilage depletion was visualized by diminished 
staining of the matrix and scored as 0 when normal and 1-3 
according to the degree of depletion (loss of staining).
For autoradiographic analysis of 35S-sulfate incorpo­
ration, radiolabeled sulfate was injected intraperitoneally 6 
hours before dissection of the knee joints. Seven micrometer 
sections of paraffin-embedded joints were mounted on gela- 
tin-coated slides which were immersed in K5 emulsion 
(Ilford, Basildon, Essex, England) and exposed for several 
weeks before being developed and stained with hematoxylin 
and eosin.
Anticytokine treatment. Antibodies were injected in­
travenously into the orbital plexus of the mice, 18-24 hours 
before induction of arthritis. Each experimental group con­
sisted of at least 7 animals.
Anti-IL-1 (a  + ß) antibody treatment. Mice were 
injected intravenously with a 200-jal standard dose of 2 mg 
purified rabbit anti-IL-1 antibodies (with a total neutralizing 
capacity of 32 ng of both subtypes of IL-1 when tested in the 
NOB1 assay; this was sufficient to completely block the 
effect of 1 ng of IL-1 a and ß on PG synthesis in vivo). 
Normal rabbit IgG or polyclonal anti-ovalbumin antibodies 
were used as controls for the nonspecific effects of treatment.
Anti-TNF and anti-IL-6 treatment. Mice were given a 
dose of 90,000 units of neutralizing monoclonal antibody 
Vlq directed against TNFa (which was sufficient to block 
7.8 fxg of TNFa in the L929 bioassay). Some mice were 
given rat anti-mouse IL-6 IgGl (with a total neutralizing 
capacity of 175 ng IL-6 in the B9 bioassay); others received 
normal rat IgG as a control.
IL-lra treatment. Mini-osmotic pumps (Alzet 1007D; 
Alza, Palo Alto, CA) were implanted into the peritoneal 
cavity 2 days before arthritis induction, and set to release 
37.5 /xg of IL-lra per hour for the next 7 days. The mean 
steady-state level of IL-lra in the blood was 4.7 jug/ml from 
the first day after implantation, as measured in the NOB1 
assay.
RESULTS
Effects of IL-1, TNF, and IL-6 on PG metabolism 
in vivo. Intraarticular injection of IL-1 a or I L - lß  
suppressed PG synthesis in patellar cartilage within a 
day of administration, in a dose-related manner (Table 
1). Marked suppression of 50-60% lasted at least 2 
days, and recovery occurred thereafter (13). Chondro­
cyte PG synthesis was suppressed by T N Fa only at 
100 ng, with lower doses having no effect after 1 day 
and actually stimulating PG synthesis after 2 days. 
Low doses of IL-6 also had no effect, and doses of 1 /¿g 
significantly enhanced PG synthesis by 32% after 2 days.
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Effect of anticytokine pretreatment on PG syn­
thesis in murine antigen- and zymosan-induced arthri­
tis. Chondrocyte PG synthesis was markedly sup­
pressed in both murine arthritis models. Pretreatment 
of the mice with anti-IL-6 or anti-TNF antibody did 
not reverse the inhibition of PG synthesis on day 2 of 
AIA and ZIA, whereas pretreatment with anti-IL-1 (a 
+ ß) did (Figure 1A). Selective elimination of either
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Figure 1. A, Role of cytokines in the suppression of proteoglycan (PG) 
synthesis in antigen-induced arthritis (AIA) or zymosan-induced arthri­
tis (ZIA). One day before arthritis induction, mice (n = 7 per group) 
received intravenous treatment with rat anti-mouse interleukin-6 
monoclonal antibodies (AIL-6; total neutralizing capacity 175 ng of 
IL-6 in the B9 bioassay), rat anti-mouse tumor necrosis factor mono­
clonal antibodies (ATNF; neutralizing capacity 90,(XX) units of T N Fa 
in the L929 bioassay), or rabbit anti-mouse IL -1 polyclonal antibodies 
(AIL-1; neutralizing capacity 32 ng of both IL-1 subtypes in the NOB1 
bioassay [a dosage found to be effective in blocking the effect of I ng of 
intraarticularly injected IL-1 on PG synthesis]). PG synthesis in the 
patellae was assessed on day 2 of arthritis, by measurement of 35S 0 4 
incorporation ex vivo. B, Relative roles of IL -la  and IL-1/3 in the 
suppression of PG synthesis in both arthritis models. One day before 
arthritis induction, mice received intravenous treatment with rabbit 
anti-IL-1 polyclonal antibodies against IL -la  (Anti-IL-la) and IL-1/3 
(Anti-IL-lb) separately or against both subtypes. Mice receiving 1 mg 
of normal rabbit IgG were used as controls. PG synthesis was assessed 
as in A.
IL -la  or IL-1/3 did not prevent the suppression of PG 
synthesis (Figure IB), indicating that both subtypes 
reached optimal effective concentrations in the joints. 
On the second day o f arthritis, the acute joint swelling 
in AIA was as severe as that in ZIA. In AIA, joint 
swelling was not significantly affected by treatment 
with anti-IL-1, anti-TNF, or anti-IL-6, and in ZIA it 
was reduced only moderately (18%) by anti-TNF, but 
not by anti-IL-1.
Effect of IL-lra on PG synthesis in AIA. In initial 
experiments, mice received bolus injections of either 2 
mg/kg or 10 mg/kg IL-lra into the peritoneal cavity, 
before and during arthritis, and PG synthesis remained 
significantly suppressed on day 2 o f arthritis (Table 2). 
In further experiments, the high amount of IL-lra 
delivered to mice via mini-osmotic pumps prevented 
the inhibition of PG synthesis on day 2 of AIA, 
confirming the results obtained after pretreatment with 
anti-IL-1 antibody in AIA.
Effects of anti-IL-1 pretreatment on cartilage 
pathology during the chronic phase of AIA. In AIA, PG 
synthesis was suppressed for at least the first 7 days of 
arthritis, whereas the suppression in ZIA was more 
transient. A single intravenous injection of anti-IL-1 
antibodies prior to arthritis induction fully prevented 
the suppression of PG synthesis for this whole period 
(results not shown). Autoradiography of 35S pulse- 
labeled knee joints on day 4 of AIA demonstrated 
marked inhibition of label incorporation, indicating 
reduced PG synthesis in the cartilage matrices. Nor­
malized incorporation was noted after anti-IL-1 pre­
treatment of the arthritic mice (Figure 2).
In the next experiment, cartilage degradation 
was accelerated; the 35S-sulfate content in prelabeled 
patellar cartilage on day 2 was reduced by a mean 
SD of 54 ± 10% in AIA and 43 ±  11% in ZIA. 
Anti-IL-1 (a + ß ) pretreatment did not prevent this in 
either form of arthritis, with losses of 50 ± 12% and 
35 ±  9% being measured; this suggests that IL-1 was 
not involved in the initiation of this process.
The combined action o f reduced synthesis and 
enhanced degradation led to a profound loss o f carti­
lage PG in AIA, which was substantially reduced by 
pretreatment with anti-IL-1, as reflected by PG mea 
surements of cartilage on days 4 and 7 of AIA (Table 
3). Histologic analysis of whole knee joints showed 
significant amelioration of the damage to the cartilage. 
Safranin O staining of the articular cartilage matrices 
was greater in the arthritic joints of anti-IL- 1-treated 
as compared with control treated mice, indicating a 
higher PG content (Figure 2).
Although blocking of IL-1 had no anti infiamma-
Tabic 2. Effects of interleukin-1 receptor antagonist (IL-lra) protein on proteoglycan (PG) synthesis in antigen-induced arthritis (AIA)*
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PG synthesis
Experiment 1,
2 mg/kg IL-1 rat
Experiment 2, 
10 mg/kg IL-1 rat
Experiment 3, 
37.5 ¿u,g/hour IL-lra§
Treatment N ormai AIA N ormai AIA Normal AIA
Saline
IL-Ira
1,172
1,107
101
141
431 691 ND
598 ± 14211 1,230 140
ND 
627 ±9311
1,270 ± 139 
1,241 ± 251
500 ± 15311 
1,268 ± 228
* PG synthesis was determined by 35S 0 4 incorporation in patellae ex vivo 48 hours after induction of AIA. Values are the mean ± SD cpm in 
at least 6 patellae.
t  IL-lra (2 mg/kg) or saline was injected into the peritoneal cavity 2 hours before arthritis induction and at 4, 10, 16, 22, 28, and 46 hours after 
arthritis induction. Total cumulative dose was —0.35 mg/mouse.
$ IL-lra (10 mg/kg) or saline was injected into the peritoneal cavity 2 hours before arthritis induction, every 3 hours the first day after arthritis 
induction, and every 6 hours the second day after arthritis induction. Total cumulative dose was ~3 mg/mouse.
§ Mini-osmotic pumps were implanted intraperitoneally 2 days before arthritis induction and set to deliver 37.5 /xg of IL-lra per hour or saline 
(control group) for the next 7 days. Total cumulative dose was ~3.6 mg/mouse. Values are representative of 3 experiments, 
li P <  0.001 versus normal contralateral joints, by Mann-Whitney U test.
tory effect on the acute inflammation, ongoing inflam­
mation of the joint was much lower in later phases of 
AIA after pretreatment with anti-IL-1. Joint swelling 
and synovitis were significantly reduced on day 7 of 
AIA (Table 3).
DISCUSSION
Direct evidence for the involvement of cyto­
kines in the process o f joint inflammation and cartilage 
destruction in RA is still lacking. We therefore under­
took to investigate, in a comparative study, the po­
tency of TN Fa, IL-1, and IL-6 in influencing chondro­
cyte function in vivo, and the effect o f selective 
blocking, in murine arthritis.
PG synthesis was markedly suppressed after 
intraarticular injections o f IL -la  or IL-lß, whereas 
higher doses of T N Fa were needed for this. In previ­
ous studies, we and others demonstrated that intraar­
ticular injection of IL-1 into synovial joints causes 
marked cartilage PG degradation and cartilage deple­
tion in various species (12-14). Of interest, this effect 
seems to be independent o f the inflammatory reaction 
(13,30). A single intraarticular injection of TNFa did 
not cause edema or enhanced PG degradation in the 
tested dose range of 1-100 ng in mice (results not 
shown). Although TNF may cause cartilage destruc­
tion in vitro (16), evidence for such a role in vivo is 
lacking (14,15).
TNF and IL-1 are potent inducers of IL-6 
production, but we clearly showed that IL-6 is not a 
destructive mediator in the murine joint and may even 
play a protective role in the joint since it stimulates PG 
synthesis. Moreover, IL-6 enhances the expression
of inhibitors o f cartilage destructive enzymes (e.g., 
tissue inhibitor o f metalloproteinases) in synovial fi­
broblasts (31).
It has been shown in studies o f rheumatoid 
synovium that TNF may be an important driving force 
in the production o f IL-1 (8). Although TNF does not 
seem to be a major cartilage destruction mediator, its 
regulating role makes it an interesting target for ther­
apy. Recent studies with chimeric antibodies to TNFa 
demonstrated their efficacy in suppressing signs of 
inflammation in short-term trials (32), but protection 
against ongoing cartilage destruction has yet to be 
demonstrated. Given the existence of separate path­
ways of IL-1 production in addition to TNF-driven 
pathways, it is tempting to suggest that blocking of 
IL-1 would be a more valid approach with respect to 
amelioration o f cartilage destruction.
Pretreatment of mice with rabbit polyclonal 
anti-IL-1 antibodies protected chondrocyte function 
in both ZIA and AIA. The IL-1 subtypes had to be 
blocked together to prevent suppression o f PG synthe­
sis in arthritis, whereas pretreatment with anti-TNF or 
anti-IL-6 antibodies had no effect. This result is con­
sistent with the relative potencies of these cytokines 
after intraarticular injection into the murine knee joint. 
Although it is reported that IL-6 is a cofactor in 
IL-l-induced suppression of PG synthesis in human 
cartilage explants (11), this has yet to be confirmed 
in vivo.
A major role of TNF and/or IL-1 in cartilage PG 
degradation during the acute phase of murine AIA or 
ZIA cannot be deduced from the present study, and 
this result is in accord with observations on AIA in the
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Figure 2. Histologic findings in the femorotibial joint. A, B, and C, Autoradiography of hematoxylin and eosin-stained sections, showing 35SCX, 
incorporation into newly synthesized PGs. D, E, and F, Safranin O-stained, fast green-counterstained sections, with diminished staining 
indicating cartilage PG loss. A and D, Normal contralateral joint. B and E, Arthritic joint on day 4 of AIA. C and F, Arthritic joint of an anti-IL-1 
treated mouse. C = cartilage; F = femur; T = tibia; M = meniscus. See Figure 1 for other definitions. (Original magnification x  100.)
rabbit (33,34). This may merely indicate that other drocyte PG synthesis can be achieved with relatively
mediators are playing a more important role, or it may small doses of IL-1, whereas considerably high IL-1
imply that IL-1 levels in AIA are too low. In that levels are needed to cause substantial PG degradation
respect it is intriguing to note that inhibition of chon- (13,16,17).
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Table 3. Effects of anti-interleukin-1 (anti-IL-1) treatment on inflammation and cartilage loss in 
antigen-induced arthritis (AIA)*
Treatment
Joint swelling 
(Tc ratio),
day 7 of AIAt
Synovitis 
(0-3 score), 
day 7 of AIAt
Glycosaminoglycan content
(¿¿g/patella)§
Day 4 of AIA Day 7 of AIA
Normal rabbit IgG 
Anti-IL-1
1.44 ± 0.25 
1.23 ± 0.1611
2.3 ± 0.8
1.3 ± 0.911
1.56 ±  0.50 
2.30 ±  0.46#
1.70 ± 0.45 
2.03 ± 0.22
* Normal rabbit IgG or antibodies against IL-1 (a -I- ß) were injected intravenously into mice 1 day 
before arthritis induction. Values are the mean ± SD.
+ Joint swelling is expressed as the ratio of the enhanced uptake of 99mtechnetium pertechnetate in the 
arthritic joint to that in the normal contralateral joint (see Materials and Methods for details).
$ Whole knee joint sections were analyzed for leukocyte infiltration into the synovium and arbitrarily 
scored from 0 (no cells) to 3 (large number of cells).
§ Glycosaminoglycan content was measured as described in Materials and Methods. Content in 
patellar cartilage of the contralateral knee joint was 2.58 ± 0.39 ¡xg on day 4, and 2.45 ± 0.31 p  g on 
day 7.
H P < 0.05 versus normal rabbit IgG-treated mice, by Mann-Whitney U test.
#  P  <  0.01 versus normal rabbit IgG-treated mice, by Mann-Whitney U test.
The overall effect o f cytokine neutralization 
seems to depend on both the type and the phase of the
treated mice was due to decreased PG degradation 
caused either directly or as a consequence of relief of
arthritis. Anti-TNF treatment in CIA resulted in the ongoing inflammation, as was shown on days 4 and 
marked amelioration of joint inflammation and carti­
lage destruction in a prevention protocol, but was 
markedly less efficient when treatment was started 
during established disease (35). In contrast, neutraliza-
7 of AIA.
The role of IL-1 in PG synthesis suppression 
was confirmed in experiments with IL -1 ra-treated 
mice. Conflicting results have been reported in the
tion of IL-1 was still efficacious when treatment was past. Lewthwaite et al (34) demonstrated blocking of
started late, and marked protection of cartilage dam­
age was observed (19,36). In the present study, anti- 
TNF pretreatment using the same antibody (Vlq) as 
was used in CIA did not diminish acute joint swelling, 
nor did it protect against cartilage damage in murine 
AIA. Furthermore, neutralization of IL-1, also using 
the same anti-IL-1 antibody as in the CIA model, did 
not reduce acute joint inflammation either, yet mark­
edly ameliorated cartilage destruction after day 2 of AIA.
These findings in the various models suggest 
that protection against cartilage destruction with neu­
tralizing anticytokine antibodies can be obtained in 
two ways. First, there is an indirect effect, when IL-1 
and/or TNF are key elements in the inflammatory 
process. Second, there is a direct effect, when inflam­
mation is caused by an excess of other mediators yet 
elimination o f a destructive mediator like IL-1 may 
still cause substantial protection. In the first situation a 
direct, destructive role of IL-1 can never be proven. 
However, in the present study of AIA and ZIA, in 
which the acute inflammation seems highly IL-1 and 
TNF independent, a key role of IL-1 in the suppres­
sion of PG synthesis has now been established. N ev­
ertheless, we cannot exclude the possibility that the 
amelioration o f cartilage degradation in the anti-IL-1-
IL-l-induced inflammation in the rabbit, but were 
unable to show protection of PG synthesis in rabbit 
AIA, in studies in which the animals were given 
repeated subcutaneous injections of human IL-lra. 
Wooley et al (18) also reported a failure to modulate 
murine AIA. We had similar, negative observations 
with repeated injections of IL-lra, but efficacy was 
clearly proven when continuous high levels were gen­
erated using Alzet mini-osmotic pumps. Using a sim­
ilar approach, we recently proved efficacy also in 
murine CIA and immune complex arthritis (van Lent 
PLEM et al and Joosten LAB et al: manuscripts in 
preparation). The relevance of this approach is obvi­
ous, given the poor pharmacokinetic profile of IL-lra. 
Moreover, continuous blocking of almost all IL-1 
receptors is needed to prevent cell activation, neces­
sitating a continuous excess of at least 1,000-10,000- 
fold amounts of IL-lra (35).
In RA, much emphasis is now focused on 
blocking of T N Fa using either chimeric antibodies or 
fusion proteins with TNF soluble receptor. In addi­
tion, initial trials are under way with IL-lra. Our 
experimental studies suggest that IL-1 is an important 
target in protection against cartilage destruction. 
Moreover, continuous administration o f high levels of
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IL-lra is needed to control IL-1 in arthritic processes, 
and it is debatable whether the IL-lra dosages used in 
clinical trials are high enough. It is hoped that antag­
onist proteins with a better profile, or selective inhib­
itors of IL-1 production, will becom e available in the 
near future.
Our present study does not demonstrate effi­
cacy of anti-IL-6 antibody treatment. Given the high 
levels of IL-6 in the circulation and in inflamed joints, 
the possibility cannot be excluded that some IL-6 
escapes neutralization. This would be particularly 
relevant with regard to local production in cartilage, 
since antibodies will not penetrate to a great extent. 
The role of IL-6 remains to be elucidated, but we 
expect that it plays a protective role in arthritis.
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